Hidenori Ibata

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 261 citations · Full text

Evaluating Prethrombotic State In Lung Cancer Using Molecular Markers

Esteban C. Gabazza, Osamu Taguchi, T Yamakami et al. · CHEST Journal · 1993 · 67 citations

Tumor Biology, Medicine, Pathology +7

Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise

T Yamakami, Osamu Taguchi, Masami Yoshida et al. · European Respiratory Journal · 1997 · 58 citations · Full text

Advanced Lung Disease, Lung Inflammation, Arterial Plasma Levels +18

Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases

Atsushi Fujiwara, Hiroyasu Kobayashi, Masahiro Masuya et al. · Respirology · 2012 · 52 citations

Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Yoshio Okano, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2013 · 39 citations

Advanced Nsclc, Medicine, Cancer Management +13